Meeting News CoverageVideo

Vismodegib for treating metastatic basal cell carcinoma

CHICAGO — Jordan B. Slutsky, MD, FAAD, clinical assistant professor, Division of Mohs Surgery & Cutaneous Oncology, Department of Dermatology, Stony Brook University Hospital, gave highlights of his presentation at the American Society for Dermatologic Surgery annual meeting on vismodegib for treating locally advanced or metastatatic basal cell carcinoma.

Vismodegib (Erivedge, Genentech) was approved by the FDA in January 2012 as therapy for adults with locally advanced or metastatic basal cell carcinoma that is not amenable to surgery or radiation.

Despite serious side effects, "a very small subset of patients" can benefit from vismodegib treatment, Slutsky said.

CHICAGO — Jordan B. Slutsky, MD, FAAD, clinical assistant professor, Division of Mohs Surgery & Cutaneous Oncology, Department of Dermatology, Stony Brook University Hospital, gave highlights of his presentation at the American Society for Dermatologic Surgery annual meeting on vismodegib for treating locally advanced or metastatatic basal cell carcinoma.

Vismodegib (Erivedge, Genentech) was approved by the FDA in January 2012 as therapy for adults with locally advanced or metastatic basal cell carcinoma that is not amenable to surgery or radiation.

Despite serious side effects, "a very small subset of patients" can benefit from vismodegib treatment, Slutsky said.

    See more from American Society for Dermatologic Surgery